sorafenib has been researched along with Rectal Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bärtschi, D; Berger, MD; Bodoky, G; Hayoz, S; Izzo, P; Klingbiel, D; Koeberle, D; Meier, UR; Plasswilm, L; Rauch, D; Roth, A; Saletti, P; Samaras, P; Schacher, S; von Moos, R; Winterhalder, RC; Yan, P; Zaugg, K; Zwahlen, D | 1 |
| Clifford, R; Gollins, S; Govindarajah, N; Parsons, JL; Vimalachandran, D; West, NP | 1 |
| Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X | 1 |
| Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D | 1 |
1 review(s) available for sorafenib and Rectal Neoplasms
| Article | Year |
|---|---|
Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoadjuvant Therapy; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Rectal Neoplasms; Sorafenib | 2018 |
3 trial(s) available for sorafenib and Rectal Neoplasms
| Article | Year |
|---|---|
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Female; Humans; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Radiotherapy, Adjuvant; Rectal Neoplasms; Sorafenib | 2018 |
Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Rectal Neoplasms; Sorafenib; Treatment Outcome | 2016 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Colonic Neoplasms; Diarrhea; Extracellular Signal-Regulated MAP Kinases; Fatigue; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Safety; Sorafenib | 2005 |